Antinociceptive effects of the selective non-peptidic δ-opioid receptor agonist TAN-67 in diabetic mice

doi:10.1016/0014-2999(95)00026-H

European Journal of Pharmacology

Volume 276, Issues 1–2, 24 March 1995, Pages 131-135

https://doi.org/10.1016/0014-2999(95)00026-H Get rights and content

Abstract

The antinociceptive potencies of 2-methyl-4aα-(3-hydroxyphenyl)-1,2,3,4,4a,5,12,12aα-octahydro-quinolino[2,3,3-g]isoquinoline (TAN-67), a non-peptidic δ-opioid receptor agonist, were examined using the acetic acid abdominal constriction test and the tail-flick test in diabetic mice. TAN-67, at doses of 3–100 mg/kg, i.p., produced a marked and dose-dependent inhibition of the number of acetic acid-induced abdominal constrictions in both non-diabetic and diabetic mice. The antinociceptive effect of TAN-67 in the acetic acid abdominal constriction test in diabetic mice was greater than that in non-diabetic mice. Indeed, the ED₅₀ (95% confidence limits) value of TAN-67 for the inhibition of acetic acid-induced abdominal constrictions in diabetic mice (6.0 (3.5–10.5) mg/kg) was significantly lower than that in non-diabetic mice (31.4 (14.2–69.4) mg/kg). The antinociceptive effect of TAN-67 was not antagonized by pretreatment with either β-funaltrexamine, a selective μ-opioid receptor antagonist, or nor-binaltorphimine, a selective κ-opioid receptor antagonist. When 7-benzylidenenaltrexone (0.3 mg/kg, s.c.), a selective δ₁-opioid receptor antagonist, was administered 10 min before treatment with TAN-67, the antinociceptive effect of TAN-67 was significantly antagonized. However, naltriben, a selective δ₂-opioid receptor antagonist, had no significant effect on the antinociceptive effect of TAN-67. Furthermore, in the tail-flick test, TAN-67 at doses of 3–30 mg/kg, i.p., also produced a marked and dose-dependent antinociceptive effect in diabetic mice, but not in non-diabetic mice. In conclusion, TAN-67 produced an antinociceptive effect through the activation of δ₁-opioid receptors. Furthermore, the results of this study support our hypothesis that mice with diabetes are selectively hyperresponsive to δ₁-opioid receptor-mediated antinociception.

References (18)

J. Kamei et al.
Paradoxical analgesia produced by naloxone in diabetic mice is attributable to supersensitivity of δ-opioid receptors
Brain Res.
(1992)
J. Kamei et al.
Effects of diabetes on stress-induced analgesia in mice
Brain Res.
(1992)
J. Kamei et al.
Streptozotocin-induced diabetes selectively alters the potency of analgesia produced by μ-opioid agonists, but not by δ-and κ-opioid agonists
Brain Res.
(1992)
J. Kamei et al.
Effect of diabetes on the antitussive effect of β-endorphin
Brain Res.
(1993)
J. Kamei et al.
Streptozotocin-induced diabetes selectively reduces antinociception mediated by μ₁-opioid receptors, but not that mediated by μ₂-opioid receptors
Neurosci. Lett.
(1994)
J. Kamei et al.
Streptozotocin-induced diabetes selectively enhances antinociception mediated by δ₁- but not δ₂-opioid receptors
Life Sci.
(1994)
P.S. Portoghese et al.
A highly selective δ₁-opioid receptor antagonist: 7-benzylidenenaltrexone
Eur. J. Pharmacol.
(1992)
M. Sofuoglu et al.
Crosstolerance studies in the spinal cord of β-FNA-treated mice provides further evidence for delta opioid receptor subtypes
Life Sci.
(1991)
K.-J. Chang et al.
A novel, potent and selective nonpeptidic delta opioid receptor agonist BW373U86
J. Pharmacol. Exp. Ther.
(1993)

There are more references available in the full text version of this article.

Cited by (64)

Synthesis of unnatural morphinan compounds to induce itch-like behaviors in mice: Towards the development of MRGPRX2 selective ligands
2022, Bioorganic and Medicinal Chemistry Letters
Mas-related G protein-coupled receptor X2 (MRGPRX2) mediates the itch response in neurons and is involved in atopic dermatitis (AD)-associated inflammation and itch. Potent and MRGPRX2-selective ligands are essential to an understanding of the detailed function of the receptor and to develop new therapeutic agents for its related diseases. (+)-TAN-67 (1), the enantiomer of the δ-opioid receptor (DOR) selective ligand (–)-TAN-67 (1), has been reported to activate MRGPRX2, although (+)-1 also interacts with DOR, which prevents investigators from interrogating the function of MRGPRX2. Here, we have succeeded in developing a novel unnatural morphinan compound (+)-2a by a transformation based on the structure of (+)-1, which removes the DOR binding affinity. (+)-2a activated both human MRGPRX2 and the mouse orthologue Mrgprb2 in in vitro experiments and induced itch-like behaviors in mice to the same extent as (+)-1. The (+)-2a-induced itch response in mice was suppressed by administration of the tripeptide QWF, an MRGPRX2/Mrgprb2 antagonist, or the antipruritic drug nalfurafine. Together, (+)-2a serves as a useful tool to elucidate the itch-related function/action of MRGPRX2 and its mouse orthologue Mrgprb2.
Zebrafish models relevant to studying central opioid and endocannabinoid systems
2018, Progress in Neuro-Psychopharmacology and Biological Psychiatry
The endocannabinoid and opioid systems are two interplaying neurotransmitter systems that modulate drug abuse, anxiety, pain, cognition, neurogenesis and immune activity. Although they are involved in such critical functions, our understanding of endocannabinoid and opioid physiology remains limited, necessitating further studies, novel models and new model organisms in this field. Zebrafish (Danio rerio) is rapidly emerging as one of the most effective translational models in neuroscience and biological psychiatry. Due to their high physiological and genetic homology to humans, zebrafish may be effectively used to study the endocannabinoid and opioid systems. Here, we discuss current models used to target the endocannabinoid and opioid systems in zebrafish, and their potential use in future translational research and high-throughput drug screening. Emphasizing the high degree of conservation of the endocannabinoid and opioid systems in zebrafish and mammals, we suggest zebrafish as an excellent model organism to study these systems and to search for the new drugs and therapies targeting their evolutionarily conserved mechanisms.
Involvement of delta opioid receptors in alcohol withdrawal-induced mechanical allodynia in male C57BL/6 mice
2016, Drug and Alcohol Dependence
As a legal drug, alcohol is commonly abused and it is estimated that 17 million adults in the United States suffer from alcohol use disorder. Heavy alcoholics can experience withdrawal symptoms including anxiety and mechanical allodynia that can facilitate relapse. The molecular mechanisms underlying this phenomenon are not well understood, which stifles development of new therapeutics. Here we investigate whether delta opioid receptors (DORs) play an active role in alcohol withdrawal-induced mechanical allodynia (AWiMA) and if DOR agonists may provide analgesic relief from AWiMA.
To study AWiMA, adult male wild-type and DOR knockout C57BL/6 mice were exposed to alcohol by a voluntary drinking model or oral gavage exposure model, which we developed and validated here. We also used the DOR-selective agonist TAN-67 and antagonist naltrindole to examine the involvement of DORs in AWiMA, which was measured using a von Frey model of mechanical allodynia.
We created a robust model of alcohol withdrawal-induced anxiety and mechanical allodynia by orally gavaging mice with 3 g/kg alcohol for three weeks. AWiMA was exacerbated and prolonged in DOR knockout mice as well as by pharmacological blockade of DORs compared to control mice. However, analgesia induced by TAN-67 was attenuated during withdrawal in alcohol-gavaged mice.
DORs appear to play a protective role in the establishment of AWiMA. Our current results indicate that DORs could be targeted to prevent or reduce the development of AWiMA during alcohol use; however, DORs may be a less suitable target to treat AWiMA during active withdrawal.
DOR<inf>2</inf>-selective but not DOR<inf>1</inf>-selective antagonist abolishes anxiolytic-like effects of the δ opioid receptor agonist KNT-127
2014, Neuropharmacology
Recently, we reported that the δ opioid receptor (DOR) agonist KNT-127 produces anxiolytic-like effects in behaving rats. Here, we report on the roles of DOR subtypes (DOR₁ and DOR₂) play in mediating KNT-127-induced anxiolytic-like effects. Pretreatment with the DOR₂-selective antagonist naltriben (NTB; 0.05 mg/kg, s.c.) completely abolished KNT-127 (3.0 mg/kg, s.c.)-induced anxiolytic-like effects in rats performing the elevated plus-maze task. By contrast, the DOR₁-selective antagonist 7-benzylidenenaltrexone (BNTX; 0.5 mg/kg, s.c.) produced no effect at a dose that completely blocked the antinociceptive effects of KNT-127. These findings were also supported by results from a light/dark test and open-field test. We clearly demonstrated that the DOR₂-selective antagonist, but not the DOR₁-selective antagonist, abolishes the anxiolytic-like effects of the DOR agonist KNT-127, suggesting different roles of these DOR subtypes in anxiety. We propose that DOR₂-selective agonists would be good candidates for future development of anxiolytic drugs.
Role of endogenous opioid peptides in the infarct size-limiting effect of adaptation to chronic continuous hypoxia
2013, Life Sciences
Citation Excerpt :
The selective δ-OR antagonist, TIPP[ψ] (H-Tyr-Ticψ [CH2NH]Phe-Phe-OH), was given at a dose of 0.5 mg/kg (Lishmanov et al., 2003). The selective δ1-OR antagonist, BNTX (7-benzylidenenaltrexone maleate), was given at a dose of 0.7 mg/kg (Maslov et al., 2009; Sofuoglu et al., 1993), and the selective δ2-OR antagonist, naltriben mesylate, was used at a dose of 0.3 mg/kg (Maslov et al., 2009; Kamei et al., 1995). The selective κ-OR antagonist, nor-binaltorphimine (nor-BNI), was administered at a dose 9 mg/kg (Birch et al., 1987; Maslov et al., 2005a, 2005b).
The objective of this study was to examine the involvement of endogenous opioid peptides and opioid receptor (OR) subtypes in the cardioprotective effect of adaptation to chronic hypoxia in rats.
Rats were exposed to continuous normobaric hypoxia (CNH; 12% oxygen) for 3 weeks. Myocardial ischemia was induced by 20-min coronary artery occlusion followed by 3-h reperfusion in anesthetized open-chest animals. Various OR antagonists were administered to rats prior to ischemia. The size of myocardial infarction and the incidence of ischemic ventricular arrhythmias were assessed. Myocardial and plasma concentrations of opioid peptides (met-enkephalin, β-endorphin, and endomorphins) were determined.
Adaptation to CNH significantly increased myocardial and plasma concentrations of opioids, potentiated their further elevation by ischemia/reperfusion, and reduced myocardial infarct size, but it did not affect the incidence of ischemic arrhythmias. The infarct size-limiting effect of CNH was abolished by OR antagonists naltrexone (non-selective), naloxone methiodide (non-selective peripherally acting), TIPP[ψ] (δ-OR), naltriben (δ₂-OR), or CTAP (μ-OR), while BNTX (δ₁-OR) and nor-binaltorphimine (κ-OR) had no effect.
The results suggest that the infarct size-limiting effect afforded by adaptation to CNH is mediated by activation of peripheral δ₂- and μ-ORs by elevated levels of endogenous opioid peptides.
Novel δ1-receptor agonist KNT-127 increases the release of dopamine and l-glutamate in the striatum, nucleus accumbens and median pre-frontal cortex
2012, Neuropharmacology
The effects of systemic δ1-agonist on neurotransmission remains obscure, since no selective δ1-agonist exists that can penetrate the blood–brain barrier. Recently, we succeeded in synthesizing a putative δ1-receptor agonist, KNT-127, which has been demonstrated the effectiveness of systemic administration against anxiety and depressive-like behavior. To clarify the functional selectivity of KNT-127 and neurotransmission regulating system of δ1-receptor, the present study investigated the interaction between KNT-127 and δ-receptor antagonists on the release of dopamine, l-glutamate and GABA in nucleus accumbens (NAc), striatum and median pre-frontal cortex (mPFC) using multi-probe microdialysis. Intraperitoneal administration of KNT-127 increased the release of dopamine and l-glutamate in three regions, but decreased and increased GABA releases in respective NAc and mPFC without affecting that in striatum. The effects of KNT-127 in the three regions were abrogated by δ1-antagonist but not by δ2-antagonist. MK801 inhibited KNT-127-induced dopamine release in striatum and NAc, but enhanced that in mPFC, inhibited KNT-127-induced mPFC GABA release without affecting KNT-127-induced GABA reduction in NAc. Muscimol enhanced KNT-127-induced dopamine release in mPFC. Sulpiride inhibited KNT-127-induced reduction of GABA release in NAc. The results indicated that KNT-127 is a selective δ1-agonist, and suggested that δ1-receptor directly activates the release of dopamine and l-glutamate in the striatum, NAc and mPFC, but not that of GABA in the three regions. δ1-receptor indirectly inhibited GABA release in NAc via activated dopaminergic transmission, while δ1-receptor indirectly enhanced GABA release in mPFC via activated glutamatergic transmission.

View all citing articles on Scopus

View full text

Regular paperAntinociceptive effects of the selective non-peptidic δ-opioid receptor agonist TAN-67 in diabetic mice

Abstract

Brain Res.

Brain Res.

Brain Res.

Brain Res.

Neurosci. Lett.

Life Sci.

Eur. J. Pharmacol.

Life Sci.

A novel, potent and selective nonpeptidic delta opioid receptor agonist BW373U86

J. Pharmacol. Exp. Ther.

Regular paper
Antinociceptive effects of the selective non-peptidic δ-opioid receptor agonist TAN-67 in diabetic mice